---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107353"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:40:44.757462+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Therapeutics Q3 net loss widens to $14.6M; cash $167.2M; pipeline updates

## Summary
- Net loss $14.6M in Q3 2025 vs $7.6M in Q3 2024; total revenue $3.3M vs $4.3M.
- Cash, equivalents and marketable securities $167.2M as of Sep 30, 2025, funding into H2 2028.
- Positive Phase 2a results for ATI-2138 in AD; Phase 2 trial in additional indication expected H1 2026.
- Top line results for bosakitug (Phase 2 AD) expected H2 2026; ATI-052 Phase 1b POC in asthma/AD expected H1 2026.
- R&D expenses rose to $13.0M (vs $6.0M) driven by clinical and preclinical activities.

## SEC filing metadata
- accession: 0001104659-25-107353
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/0001104659-25-107353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/acrs-20251106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107353
- JSON: https://secwatch.observer/filing/0001104659-25-107353.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.